Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
129.48
+0.11 (+0.09%)
Official Closing Price
Updated: 4:10 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat Week in Review – 12/18 - 12/22
December 23, 2023
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
December 22, 2023
From
Daiichi Sankyo
Via
Business Wire
Merck Provides U.S. Regulatory Update on Gefapixant
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
December 19, 2023
From
Merck & Co., Inc.
Via
Business Wire
C4 Therapeutics blasts off: what's next?
December 18, 2023
As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume.
Via
MarketBeat
Topics
ETFs
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
December 18, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
December 15, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
December 14, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
December 14, 2023
Via
ACCESSWIRE
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
December 11, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
December 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
December 07, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
November 30, 2023
From
Merck & Co., Inc.
Via
Business Wire
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
November 29, 2023
From
Amazon.com, Inc.
Via
Business Wire
Merck Announces First-Quarter 2024 Dividend
November 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
November 28, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire Caraway Therapeutics, Inc.
November 21, 2023
From
Merck & Co., Inc.
Via
Business Wire
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
November 16, 2023
From
Merck & Co., Inc.
Via
Business Wire
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
3 S&P stocks with growth to weather a downturn
November 13, 2023
S&P 500 components Broadcom, McCormick and Merck stocks are diverse stocks worth tracking for investors seeking strong earnings and dividend growth.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
November 10, 2023
From
Merck & Co., Inc.
Via
Business Wire
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Merck to Participate in the Jefferies London Healthcare Conference
November 08, 2023
From
Merck & Co., Inc.
Via
Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Merck to Participate in the UBS BioPharma Conference
November 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
November 01, 2023
From
Merck & Co., Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.